Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02784483
Title Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Yale University
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.